Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813551 | 1.00 | CTSK (0.44) | CTSKLTA4HGRNSORT1CTSS | |
| SCHEMBL21814100 | 1.00 | CTSK (0.44) | CTSKLTA4HGRNSORT1CTSS | |
| SCHEMBL4064294 | 0.87 | CPN1 (0.49) | CTSKANPEPEPHX1 | |
| SCHEMBL27180326 | 0.85 | CTSK (0.38) | CTSKLTA4HGRNSORT1 | |
| SCHEMBL27180327 | 0.85 | CTSK (0.38) | CTSKLTA4HGRNSORT1 | |
| SCHEMBL26165576 | 0.81 | CTSK (0.43) | CTSKLTA4HGRNSORT1CTSS | |
| SCHEMBL27180719 | 0.79 | CTSK (0.47) | CTSKCTSSEPHX1L3MBTL1KMT2A | |
| SCHEMBL16164574 | 0.78 | REN (0.34) | CTSKLTA4HGRNSORT1CTSS | |
| SCHEMBL4976854 | 0.77 | CTSK (0.39) | CTSKLTA4HCTSSEPHX1CTSL | |
| SCHEMBL4976850 | 0.77 | CTSK (0.39) | CTSKLTA4HCTSSEPHX1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | CTSK 1262/4885LTA4H 384/4885GRN 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.